Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Investor Presentation (March 2024)

17 slides from Kazia Therapeutics's investor presentation, March 2024

  1. Slide 1: A Diversified, Clinical-Stage Oncology Drug Development Company

    A Diversified, Clinical-Stage Oncology Drug Development Company EVT-801: A clinical stage, first-in-class small molecule targeting tumor (lymph)-angiogenesis Non-confidential deck March 2024 NASDAQ: KZIA | Twitter: @KaziaTx

  2. Slide 2: Forward-Looking Statements

    Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statem

  3. Slide 3: EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis

    EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 Oral Presentation Expected to minimise off-target toxicities Administered by mouth once or twice daily Strong IP Protection Inhibits lymphangiogenesi

  4. Slide 4: Targeting angiogenesis is a well-established approach in the treatment of cancer

    Targeting angiogenesis is a well-established approach in the treatment of cancer Product Company Target Indications Annual Sales (US$)* • Colorectal cancer • Lung cancer VEGF-A • Breast cancer $7 billion • Other cancers VEGFRs • Hepatocellular carcinoma PDGFRs • Renal cell carcinoma $1 billion RAF k

  5. Slide 5: Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges

    Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges Angiogenesis inhibitors work by 1 Tumour Hypoxia reducing the formation of new blood vessels around the tumour, starving it Sustained tumour hypoxia Limited of vital nutrients needed for tumour activates ada

  6. Slide 6: EVT801: A differentiating anti-tumour approach

    EVT801: A differentiating anti-tumour approach Inhibition of tumour escape and metastasis • Stabilisation of tumour vasculature 1 • Inhibition of (lymph)-angiogenesis • Avoidance of hypoxia decreases potential for metastatic spread Increase in anti-tumour immune activity • No impact on T-cells viabi

  7. Slide 7: EVT801 selectively inhibits VEGFR3

    EVT801 selectively inhibits VEGFR3 Avastin Lucentis (bevacizumab) (ranibizumab) VEGF-B VEGF-A VEGF-D VEGF-E VEGF-C Sutent (sunitinib) EVT801 VEGFR1 VEGFR2 VEGFR3 Nexavar (sorafenib) Inlyta Cell Survival Signal Modulation Angiogenesis (axitinib) Votrient (Lymph)- Vasculogenesis angiogenesis (panzopan

  8. Slide 8: EVT801 has a unique mode of action compared to angiokinase inhibitors

    EVT801 has a unique mode of action compared to angiokinase inhibitors Unique mode of action: Characteristics EVT801 Angiokinase inhibitors • Tumour blood vessel normalization through avoidance of • Tumour escape due to only transient tumour Blood vessel normalization hypoxia decreases potential for

  9. Slide 9: Current anti-VEGF agents have limitations

    Current anti-VEGF agents have limitations Multi-VEGF Target characteristic EVT801 inhibitors Cellular in vitro IC50 (nM) 🗸🗸 🗸🗸 Compound VEGFR2 VEGFR3 Potent small molecule VEGFR3 inhibitor EVT801 241 21 🗸🗸 High selectivity over other VEGF receptors and TK panel X EVT801 metabolite 424 37…

  10. Slide 10: Unlike many mTKIs, EVT801 does not inhibit CD3+ T-cell function

    Unlike many mTKIs, EVT801 does not inhibit CD3+ T-cell function % Live Cells % Cells Compound (0 – 100uM) • Sorafenib and axitinib inhibit T-cell proliferation • EVT801 and its metabolite have no negative impact on T-cell viability and proliferation (as well as Lenvatinib) 10

  11. Slide 11: Preclinical data confirms activity of EVT801 (1/2)

    Preclinical data confirms activity of EVT801 (1/2) Dramatic single-agent activity in DEN-induced Hepatocellular carcinoma model Tumour Growth Metastasis Experimental Methods Total Tumour Volume Number of Tumours in the Liver • Syngeneic mouse model 85% reduction 50% reduction • HCC chemically induce

  12. Slide 12: Preclinical data confirms activity of EVT801 (2/2)

    Preclinical data confirms activity of EVT801 (2/2) Synergistic activity in combination with anti-CTLA4 mAb Tumour Volume (mm3) 500 Experimental Methods Vehicle • Orthotopic tumour mouse model EVT801 • 4T1 tumour cells inoculated in BALB/c 400 anti-CTLA4 mice (mammary fat pad) EVT801 + anti-CTLA4 • T

  13. Slide 13: Phase 1 dose-finding trial ongoing in France – KZA 0801-101

    Phase 1 dose-finding trial ongoing in France – KZA 0801-101: NCT05114668 Target population: Histologically-confirmed advanced or metastatic solid tumours, unresponsive to standard treatment, or for whom no standard treatment is available or appropriate STAGE 1 STAGE 2 Monotherapy dose escalation Bio

  14. Slide 14: Exploratory biomarkers during Phase 1 clinical trial

    Exploratory biomarkers during Phase 1 clinical trial EVT801 Biomarkers Strategy 1 3 Patient characterization based on VEGFR-3 Circulating endpoint /CAIX/CD8 expression on archival tissues biomarkers: and/or biopsies • Immunomonitoring based • VEGFR-3 protein signature by histology on CD8pos T-cells

  15. Slide 15: Status of Phase 1 Clinical Study: KZA 0801-101

    Status of Phase 1 Clinical Study: KZA 0801-101 EVT801 Clinical Study Protocol Number Study Name Study Update KZA 0801-101 A Phase 1, First in Human, Open Label Study to Assess the To date 32 patients included in the study Safety, Tolerability, and Pharmacokinetics of EVT801 in • 26 patients treated

  16. Slide 16: Key Points

    Key Points 1 Well-understood mechanism (anti-angiogenesis) with unique differentiating feature (high VEGFR3 selectivity) 2 Strong preclinical data package, with evidence of activity in multiple tumours and favorable toxicology 3 Potential for combination use with immuno-oncology therapies Ongoing ph

  17. Slide 17: www.kaziatherapeutics.com

    www.kaziatherapeutics.com info@kaziatherapeutics.com

Kazia Therapeutics — Investor Presentation (March 2024) on 6ix